Answers are grounded in this paper and cite their sources.
Primary breast mucinous cystadenocarcinoma (BMCA) is a rare entity. Herein, we report a case of HER2-positive BMCA in a 59-year-old postmenopausal woman who presented with a 4-year history of a painless mass in the right breast. The tumor exhibited multiloculated cystic structures lined by columnar epithelium with abundant intracytoplasmic and luminal mucin, mild to severe nuclear atypia, focal stratification, and papillary projections protruding into the lumen. The tumor periphery showed signs of concomitant ductal carcinoma in situ. The tumor (BMCA) displayed diffuse immunohistochemical positivity for CK7 and TRPS1, as well as with HER2 (3 + ), with HER2 gene amplification confirmed by fluorescence in situ hybridization (FISH); negativity for CK20, CDX-2, Villin, PAX8, TTF1, and SOX10; and Ki-67 proliferation index of 70% (in hot spots). The histopathological features, clinical–radiological correlation, and specific immunophenotypic profile established the diagnosis of primary BMCA. Notably, all BMCA cases tested for SOX10 to date have been negative (10/10), including the present HER2-positive case—distinct from conventional triple-negative breast cancer (TNBC), in which SOX10 is typically expressed, representing a potential diagnostic pitfall. TRPS1 showed diffuse positivity in all tested cases (11/11), supporting its potential utility in distinguishing primary BMCA from tumors of other origins.A pooled analysis of 43 BMCA cases, mostly derived from the literature and including our current case, with available Ki-67 data revealed high proliferative activity (≥ 30%) in 76.7% of cases, challenging the traditional perception of BMCA as an indolent tumor. Despite high proliferative indexes, most patients—including ours, who remained recurrence-free at 42 months after breast-conserving surgery without adjuvant therapy—demonstrated favorable outcomes. This apparent discordance between the high proliferative activity and an indolent clinical course suggests a unique biological behavior of BMCA, warranting further investigation into the underlying mechanisms. Molecular studies have indicated that BMCA frequently harbors alterations in TP53, the PI3K/AKT pathway, and RB1, whereas KRAS mutations are uncommon. These findings underscore the biological heterogeneity of BMCA and support the integration of histopathological, immunophenotypic, and molecular profiling for precise risk stratification and personalized targeted therapy.
No takes yet. Share an insight, caveat, or question.
Jian et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: